RTTNews | Aug 9, 2021 08:22AM EDT

08:22 Monday, August 9, 2021 (RTTNews.com) - INOVIO (INO) has received regulatory allowance in China for two clinical trials investigating heterologous boosting with INO-4800, the company's DNA vaccine candidate for COVID-19. The regulatory approval allows the initiation of Advaccine-sponsored open-label, positive-control trials to evaluate the safety, tolerability, and immunogenicity of mixed boosted regimens. The studies will examine the safety, tolerability and immunogenicity of heterologous prime-boost sequential immunizations using INO-4800 and CoronaVac, an inactivated COVID-19 vaccine developed by Sinovac.

Joseph Kim, CEO of INOVIO, said, "If approved, we believe INO-4800 will be well-positioned to serve the vaccine needs of the global community as both a primary and a booster vaccine."

Read the original article on RTTNews ( https://www.rttnews.com/3217328/inovio-expands-partnership-with-advaccine-to-explore-heterologous-prime-boosting-using-ino-4800.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved